Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProPhase Labs, Inc.PRPH · Entity 8699 | CHIEF FINANCIAL OFFICER | April 04, 2023 | April 06, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProPhase Labs, Inc.
Report date April 04, 2023 · Filed April 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.00 · Expires 2031-04-03 | Direct | 50,000 |
Reported balance
After 2023-04-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-04-04 · Grant · Acquired 50,000 · Balance 50,000 F1: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase the Issuer's common stock that will vest in five equal annual installments beginning April 5, 2024, subject to the Reporting Person's continued employment with the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase the Issuer's common stock that will vest in five equal annual installments beginning April 5, 2024, subject to the Reporting Person's continued employment with the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 04, 2023 Filed Apr 6, 2023 20:20 UTC | ProPhase Labs, Inc. PRPH · Entity 8699 | GrantOption (right to buy) · Derivative | 50,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001493152-23-011249 · ownership.xml · derivative · entry 1 Morse Robert A. Jr. · CIK 0001960049 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-04-03 F1 · derivative.exercise_date: The transaction reported in this row involves a grant by the Issuer to the Reporting Person of options to purchase the Issuer's common stock that will vest in five equal annual installments beginning April 5, 2024, subject to the Reporting Person's continued employment with the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.